4.5 Review

TGF-Beta: a Master Switch in Tumor Immunity

Journal

CURRENT PHARMACEUTICAL DESIGN
Volume 18, Issue 27, Pages 4126-4134

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161212802430378

Keywords

TGF-beta; natural killer; dendritic cells; CD8(+) T cells; Th1; Th2; Th17; treg cells

Ask authors/readers for more resources

The capacity of the immune system to distinguish foreign from self-antigen, and to subsequently eliminate the threat of disease without injuring the host is crucial for survival. It also serves to defend against tumor formation and progression via a process termed cancer immunosurveillance. Innate and adaptive immune cell types and effector molecules collectively function as extrinsic tumor-suppressor mechanisms. However, tumors may escape immunesurveillance through a variety of mechanisms that create a local microenvironment that is unfavorable for effective tumor immunity. Transforming growth factor beta (TGF-beta) has pleiotropic effects on the immune system, and is recognized as one of the most potent immunosuppressive agents in facilitating oncogenesis. The TGF-beta pathway promotes cancer progression by concomitantly enhancing tumor metastases while inhibiting the protective host immunity. In this review, we discuss mechanisms through which TGF-beta interferes with the development of an anti-tumor immunity and potential means through which to circumvent its activity in order to define more effective cancer immunotherapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available